Ascending Dosing Will Start in Trial of NVG-291 in Healthy Volunteers

Ascending Dosing Will Start in Trial of NVG-291 in Healthy Volunteers

315374

Ascending Dosing Will Start in Trial of NVG-291 in Healthy Volunteers

NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions, in a Phase 1 trial with healthy volunteers. This multiple ascending dose (MAD) part, in which participants will receive increasing doses of NVG-291 or a placebo for 14 days, follows positive results from the trial’s single dosing part. The company is now screening healthy postmenopausal women for the MAD portion…

You must be logged in to read/download the full post.